Herpes Zoster Market

Market Overview:

The 7 major herpes zoster markets are expected to exhibit a CAGR of 2.61% during 2024-2034.

The herpes zoster market has been comprehensively analyzed in IMARC's new report titled "Herpes Zoster Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Herpes zoster, also known as shingles, is a type of viral infection that damages the skin and nerves. This condition typically manifests as a painful rash that appears in a localized area of the body, particularly on one side of the torso. Individuals suffering from the ailment may also experience itching, tingling, and burning sensations, as well as general flu-like symptoms, including fever, headache, fatigue, etc. In most cases, the rash develops into small, fluid-filled blisters, which eventually begin to dry out and crust over. The diagnosis of herpes zoster involves a medical evaluation based on the patient's indications and physical examination. Several blood workups, such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assays, are also performed to measure the levels of antibodies that are specific to the varicella-zoster virus in the blood. Additionally, the healthcare professional may conduct a Tzanck smear analysis by obtaining a sample from a skin blister and examining it under a microscope to check for the presence of abnormal multinucleated giant cells indicative of the condition. 

The increasing cases of chickenpox infection, in which the virus does not entirely leave the body and instead retreats to sensory nerve cells, are primarily driving the herpes zoster market. In addition to this, the expanding geriatric population, who are more prone to physical and emotional stress that can disrupt the immune system and potentially trigger viral reactivation, is creating a positive outlook for the market. Moreover, the widespread adoption of recombinant zoster vaccine owing to its various advantages, like long-lasting protection, enhanced efficacy, and minimal side effects, is further bolstering the market growth. Apart from this, the rising usage of topical antiviral creams, such as acyclovir and penciclovir, which can be applied directly on the rash to inhibit the replication of the virus, thereby reducing the severity and duration of the disease, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of polymerase chain reaction (PCR) techniques to aid in early diagnosis by detecting even low levels of viral DNA or RNA in the patient's sample is expected to drive the herpes zoster market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the herpes zoster market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for herpes zoster and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the herpes zoster market in any manner.

Recent Developments:

• In May 2023, Immorna stated that the first patient was dosed in the Company's First-In-Human (FIH) Phase 1 multi-center research of JCXH-105, a self-replicating RNA vaccine being developed for the prevention of Shingles (herpes zoster).
• In February 2023, Pfizer Inc. and BioNTech SE disclosed the launch of a Phase 1/2 trial to investigate the tolerability, safety, and immunogenicity of the companies' mRNA vaccine candidates against herpes zoster.

Key Highlights:

• The incidence of herpes zoster differs by age and is roughly 2-9 cases per 1,000 US population per year.
• Herpes zoster is most common between the ages of 60-69, with a low frequency in individuals over 80.
• Women had a higher incidence of herpes zoster than men (12.6/1000-person year vs. 8.3/1000-person year).
• The urban zone had a higher incidence of herpes zoster (7.65/1000-person year) than the rural area (2.06/1000-person year).
• Recurrent zoster occurs nearly exclusively in immunocompromised individuals.

Drugs:

Valtrex refers to an antiviral medication that contains the active ingredient, valaciclovir. It is used to treat Herpes Zoster. In the body, valaciclovir is broken down into two substances: aciclovir and valine (an amino acid). Aciclovir is an antiviral that acts by inhibiting an enzyme that viruses require to synthesize DNA. The inhibition of DNA creation prevents viruses from multiplying.

CRV-101 is under clinical development by Curevo for the prevention of herpes zoster (shingles). The vaccine candidate is a subunit vaccination. It is delivered by the intramuscular method.

JCXH-105 is a self-replicating RNA (srRNA)-based vaccine designed to prevent herpes zoster currently being developed by Immorna Biotherapeutics Inc. Unlike conventional mRNA vaccines, self-replicating RNA produces double-stranded RNA intermediates during srRNA replication in transfected cells. This process causes a high innate immune response, which subsequently amplifies the adaptive immunological response to perform desired effector tasks, particularly through T cells, which are the primary mechanism of immune protection against the disease.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the herpes zoster market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the herpes zoster market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current herpes zoster marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the herpes zoster market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the herpes zoster market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the herpes zoster market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of herpes zoster across the seven major markets?
• What is the number of prevalent cases (2018-2034) of herpes zoster by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of herpes zoster by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with herpes zoster across the seven major markets?
• What is the size of the herpes zoster patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of herpes zoster?
• What will be the growth rate of patients across the seven major markets?
   

Herpes Zoster: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for herpes zoster drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the herpes zoster market?
• What are the key regulatory events related to the herpes zoster market?
• What is the structure of clinical trial landscape by status related to the herpes zoster market?
• What is the structure of clinical trial landscape by phase related to the herpes zoster market?
• What is the structure of clinical trial landscape by route of administration related to the herpes zoster market?